MetLife Investment Management’s Medtronic MDT Stock Holding History

MetLife Investment Management’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26M	Sell	299,560 -7,910	-3%	-$758K	0.13%	116
2025 Q4	$29.5M	Sell	307,470 -10,452	-3%	-$1.02M	0.14%	102
2025 Q3	$30.3M	Sell	317,922 -8,872	-3%	-$816K	0.15%	96
2025 Q2	$28.5M	Sell	326,794 -6,285	-2%	-$533K	0.17%	90
2025 Q1	$29.9M	Sell	333,079 -6,393	-2%	-$572K	0.16%	96
2024 Q4	$27.1M	Buy	339,472 +5,939	+2%	+$514K	0.15%	102
2024 Q3	$30M	Sell	333,533 -20,669	-6%	-$1.74M	0.17%	93
2024 Q2	$27.9M	Buy	354,202 +42,890	+14%	+$3.52M	0.17%	99
2024 Q1	$27.1M	Sell	311,312 -11,646	-4%	-$994K	0.18%	91
2023 Q4	$26.6M	Buy	322,958 +319,981	+10,748%	+$24.4M	0.19%	87
2023 Q3	$233K	Sell	2,977 -334,671	-99%	-$28M	﹤0.01%	2115
2023 Q2	$29.7M	Sell	337,648 -5,778	-2%	-$497K	0.22%	78
2023 Q1	$27.7M	Sell	343,426 -3,865	-1%	-$315K	0.2%	83
2022 Q4	$27M	Sell	347,291 -5,573	-2%	-$452K	0.2%	88
2022 Q3	$28.5M	Sell	352,864 -8,449	-2%	-$759K	0.24%	72
2022 Q2	$32.4M	Sell	361,313 -4,508	-1%	-$457K	0.25%	69
2022 Q1	$40.6M	Buy	365,821 +68,476	+23%	+$7.23M	0.26%	65
2021 Q4	$30.8M	Sell	297,345 -6,190	-2%	-$717K	0.25%	66
2021 Q3	$38M	Sell	303,535 -8,389	-3%	-$1.09M	0.34%	52
2021 Q2	$38.7M	Sell	311,924 -9,320	-3%	-$1.17M	0.34%	52
2021 Q1	$37.9M	Sell	321,244 -5,644	-2%	-$661K	0.35%	48
2020 Q4	$38.3M	Sell	326,888 -13,930	-4%	-$1.53M	0.36%	47
2020 Q3	$35.4M	Sell	340,818 -9,922	-3%	-$996K	0.39%	45
2020 Q2	$32.2M	Buy	350,740 +5,241	+2%	+$503K	0.37%	47
2020 Q1	$31.2M	Sell	345,499 -10,571	-3%	-$1.12M	0.42%	41
2019 Q4	$40.4M	Sell	356,070 -9,047	-2%	-$993K	0.42%	37
2019 Q3	$39.7M	Sell	365,117 -4,432	-1%	-$462K	0.44%	37
2019 Q2	$36M	Sell	369,549 -11,706	-3%	-$1.07M	0.39%	42
2019 Q1	$34.7M	Sell	381,255 -2,846	-0.7%	-$255K	0.38%	43
2018 Q4	$34.9M	Sell	384,101 -8,774	-2%	-$820K	0.42%	41
2018 Q3	$38.6M	Buy	+392,875	New	+$36.3M	0.4%	42

Other funds holding MDT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MetLife Investment Management's MDT Position: Q1 2026 in Review

MetLife Investment Management reduced its Medtronic (MDT) stake by 2.6% in Q1 2026, selling an estimated $758K and leaving 299,560 shares worth $26M. The position accounts for 0.13% of the portfolio, ranked #116.

MetLife Investment Management first reported a position in MDT in Q3 2018 and has held it in 31 quarters since. The position peaked at $40.6M in Q1 2022. 2,229 funds tracked by Wall St. Rank hold MDT as of Q1 2026.

MetLife Investment Management held 299,560 shares of Medtronic worth $26M as of Q1 2026.
MetLife Investment Management sold 7,910 Medtronic shares in Q1 2026, an estimated $758K.
Medtronic made up 0.13% of MetLife Investment Management's portfolio in Q1 2026, its #116 holding.
MetLife Investment Management first reported a position in Medtronic in Q3 2018 and has held it in 31 quarters since.
MetLife Investment Management's Medtronic position peaked at $40.6M in Q1 2022.
2,229 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.